Avid Bioservices Stock Forecast, Price & News

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices or view top-rated stocks.

What stocks does MarketBeat like better than Avid Bioservices?

Wall Street analysts have given Avid Bioservices a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avid Bioservices wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, December 1st 2021.
View our earnings forecast for Avid Bioservices.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Tuesday, September, 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The biopharmaceutical company had revenue of $30.75 million for the quarter, compared to analyst estimates of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 19.89% and a net margin of 12.63%. During the same period in the previous year, the business posted $0.06 earnings per share.
View Avid Bioservices' earnings history.

How has Avid Bioservices' stock price been impacted by Coronavirus (COVID-19)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDMO shares have increased by 389.4% and is now trading at $22.07.
View which stocks have been most impacted by COVID-19.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2022 earnings guidance on Thursday, September, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $115.83 million.

What price target have analysts set for CDMO?

3 analysts have issued twelve-month target prices for Avid Bioservices' stock. Their forecasts range from $27.00 to $29.00. On average, they expect Avid Bioservices' share price to reach $28.00 in the next year. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Avid Bioservices or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:

• Nicholas S. Green, President, Chief Executive Officer & Director
• Richard A. Richieri, Chief Operating Officer
• Daniel Ryan Hart, Chief Financial Officer (LinkedIn Profile)
• Nick Ferguson, Executive Director-Information Technology
• Mark R. Ziebell, Secretary, Vice President & General Counsel (LinkedIn Profile)

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Avid Bioservices' key competitors?

Some companies that are related to Avid Bioservices include I-Mab (IMAB), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Mawson Infrastructure Group (WIZP), TG Therapeutics (TGTX), Cerevel Therapeutics (CERE), Arvinas (ARVN), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Hypera (HYPMY), 23andMe (ME), Turning Point Therapeutics (TPTX), Arena Pharmaceuticals (ARNA), Karuna Therapeutics (KRTX) and Galapagos (GLPG).
View all of CDMO's competitors.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.01%), BlackRock Inc. (7.09%), Vanguard Group Inc. (5.13%), State Street Corp (4.11%), AltraVue Capital LLC (3.58%) and Ranger Investment Management L.P. (3.22%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Kornitzer Capital Management Inc. KS, JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Cinctive Capital Management LP, AltraVue Capital LLC, Pier Capital LLC, and Kennedy Capital Management Inc.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, Mark R Ziebell, and Nicholas Stewart Green.
View insider buying and selling activity for Avid Bioservices or view top insider-selling stocks.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Bank of Montreal Can, Invesco Ltd., Jennison Associates LLC, FMR LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Morgan Stanley. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $22.07.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $1.35 billion and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 255 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

Where are Avid Bioservices' headquarters?

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at (714) 508-6100 or via email at [email protected].